I hear ya, and I hear everyone's concerns about Nasdaq, and while I agree there are some definite benefits to it, I don't believe it will make Leronlimab any more effective.
Sure, the launch will be better on nasdaq. But 3 years from now I wont care if we uplisted in September or November.